Targeting mTOR dependency in pancreatic cancer - Wikidata - wikimedia - TriplyDB

Targeting mTOR dependency in pancreatic cancer

Targeting mTOR dependency in pancreatic cancer

http://www.wikidata.org/entity/Q34092334

about

Targeting mTOR in Pancreatic Ductal Adenocarcinoma Biomarkers and Targeted Therapy in Pancreatic Cancer Genomic alterations in pancreatic cancer and their relevance to therapy GEMMs as preclinical models for testing pancreatic cancer therapies Phosphorylation by mTORC1 stablizes Skp2 and regulates its oncogenic function in gastric cancer Diabetes, pancreatic cancer, and metformin therapy.Pancreatic cell plasticity and cancer initiation induced by oncogenic Kras is completely dependent on wild-type PI 3-kinase p110α Low molecular weight protein tyrosine phosphatase (LMWPTP) upregulation mediates malignant potential in colorectal cancer.Metformin Increases Sensitivity of Pancreatic Cancer Cells to Gemcitabine by Reducing CD133+ Cell Populations and Suppressing ERK/P70S6K Signaling.Expression of PTEN and KAI1 tumor suppressor genes in pancreatic carcinoma and its association with different pathological factors.Rapamycin and WYE-354 suppress human gallbladder cancer xenografts in mice Molecular signature of pancreatic adenocarcinoma: an insight from genotype to phenotype and challenges for targeted therapy.Analysis of Important Gene Ontology Terms and Biological Pathways Related to Pancreatic Cancer.Association of peripheral leukocyte telomere length and its variation with pancreatic cancer and colorectal cancer risk in Chinese population.Pancreatic cancer: from bench to bedside.Targeted next generation sequencing of endoscopic ultrasound acquired cytology from ampullary and pancreatic adenocarcinoma has the potential to aid patient stratification for optimal therapy selection.mTOR in health and in sickness.Metformin and pancreatic cancer: Is there a role?Metformin in pancreatic cancer treatment: from clinical trials through basic research to biomarker quantification.Insulin promotes proliferation and fibrosing responses in activated pancreatic stellate cells.Inhibition of mTORC2 component RICTOR impairs tumor growth in pancreatic cancer models.mTORC2 Signaling Drives the Development and Progression of Pancreatic Cancer.Intravital FRAP Imaging using an E-cadherin-GFP Mouse Reveals Disease- and Drug-Dependent Dynamic Regulation of Cell-Cell Junctions in Live Tissue.Identification and Analysis of Novel Inhibitors against NS3 Helicase and NS5B RNA-Dependent RNA Polymerase from Hepatitis C Virus 1b (Con1).Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis.MTOR inhibitor-based combination therapies for pancreatic cancer.Regenerative proliferation of differentiated cells by mTORC1-dependent paligenosis.Potent effects of dioscin against pancreatic cancer via miR-149-3P-mediated inhibition of the Akt1 signalling pathway.CSF1R+ Macrophages Sustain Pancreatic Tumor Growth through T Cell Suppression and Maintenance of Key Gene Programs that Define the Squamous Subtype.A subset of metastatic pancreatic ductal adenocarcinomas depends quantitatively on oncogenic Kras/Mek/Erk-induced hyperactive mTOR signalling.Next generation sequencing of pancreatic ductal adenocarcinoma: right or wrong?MiR-142-3p is downregulated in aggressive p53 mutant mouse models of pancreatic ductal adenocarcinoma by hypermethylation of its locus.Intravital Imaging to Monitor Therapeutic Response in Moving Hypoxic Regions Resistant to PI3K Pathway Targeting in Pancreatic Cancer.Naturally occurring compounds as pancreatic cancer therapeutics

P2860

Q26747291-0084A00C-8483-4FAD-9E2A-DCA35F61F752 Q26752755-A9F08F17-B13F-4C1C-B341-E15513C9FD3B Q26781443-7D3A9055-E866-4143-8615-C05A19D06798 Q26781848-F7C475EF-41BC-4D5C-8791-FB4ADE4901F1 Q33608923-E4A34B50-F4AC-4D8F-936A-02A9D45C2E0C Q34471173-52AC8659-DF3C-41D6-8A98-93361AE23E2D Q34590266-97E50B7E-BEF9-4FA8-AF98-BCCF61AC11B0 Q35781576-D76334CD-C591-48BD-B0E6-654F910580DF Q36099266-227AF2C9-EE2D-49D8-A090-B1D16F4BA485 Q36502768-F1606B5F-5C16-4DDC-A3CB-B0CF4CC1AE58 Q36544718-515E0EF1-BF32-41E5-A3DB-5DB51D92AA12 Q37176648-A3CC7B8F-D003-4F05-B47D-1B0C9F4C3278 Q37430812-9A719099-E617-48E9-8149-A9D52E97D30A Q37437582-F4968300-351C-452E-827C-51B12FFD8A89 Q37570357-4597DBD0-3548-4DBD-A9BA-1C3D04B31626 Q37688099-F2AF548D-A02F-40E9-98A5-A98EF56BC1CA Q38590634-A6131923-928C-4F0E-941F-47E1655A07AD Q38689022-EADBB1C2-8267-4369-BFDA-ADD24ACFEFDD Q38829871-C932CC9D-940F-45D5-B4D9-E1F3914C7904 Q39408469-9C0E2A10-08CF-49E3-B8AA-C2525C45D8B7 Q41781449-68399B42-2289-404E-A010-3D78A0DE32F0 Q42359443-DF7F0FAF-9406-478D-B27D-DCD7CEB3E232 Q42678959-E78408FE-1B37-4003-9706-D602E3B01EEF Q45323754-E8C14538-29CF-49BD-A4BD-5EC160ACADD6 Q45987365-C515B94B-B2DA-4735-843D-3471A8B784E1 Q49560871-2DC3A9BC-4F96-4FBC-B48B-09CFA6596C7D Q50422422-EE268194-7415-4811-B68D-2D6EC8B01BB5 Q51186424-35641C4C-DF74-4E8A-8D54-2C1F67194669 Q53069544-599F59F0-CCCD-4232-8267-2018E10EA72D Q53224745-9D58612A-515A-4FBC-84ED-53F855461EC6 Q54277914-E84C8918-F67B-43DC-80D1-D8880769FFD8 Q55021852-B7C33296-E063-406C-AB10-27228B25CD4B Q55400356-B8B3250B-C97A-4F79-9DE0-A990CF26FDF9 Q59128443-38AD9DB9-2FAF-4ABB-9303-B1417D16F9B6

P2860

Targeting mTOR dependency in pancreatic cancer

http://www.wikidata.org/entity/Q34092334

description

2014 nî lūn-bûn

@nan

2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Targeting mTOR dependency in pancreatic cancer

@ast

Targeting mTOR dependency in pancreatic cancer

@en

Targeting mTOR dependency in pancreatic cancer

@nl

type

label

Targeting mTOR dependency in pancreatic cancer

@ast

Targeting mTOR dependency in pancreatic cancer

@en

Targeting mTOR dependency in pancreatic cancer

@nl

prefLabel

Targeting mTOR dependency in pancreatic cancer

@ast

Targeting mTOR dependency in pancreatic cancer

@en

Targeting mTOR dependency in pancreatic cancer

@nl

P1433

Q34092334-29291639-75E7-47A8-AD36-7A98816032E4

P1476

Q34092334-80C1FA15-5C68-499B-BC5B-190A683ADD60

P2093

Q34092334-2F747A7B-5850-4A88-842B-FF23BF84B0DF

Q34092334-3ED5CC54-7E86-4DB2-BD78-1DFA1E9FBC57

Q34092334-52BFD74B-E783-4959-B819-873D77015FA7

Q34092334-8E1D1A00-81E0-4C7E-A40C-97ED0B5B13BC

Q34092334-948A6962-402F-4A5E-A009-4F15BEBAD0FD

Q34092334-A3303E82-8FC2-456B-AC70-2BA8E6C94512

Q34092334-AFDF0104-1202-4BAE-A0BF-3E97D1C76F28

Q34092334-BC671A9D-09C9-480D-BD22-A4574AA82C42

Q34092334-D38FAD22-F9F0-4227-B092-3BC63B930F68

Q34092334-E22CE5C6-2B50-471D-B072-8F455F1975C8

P2860

Q34092334-06D497DC-3CCE-4C9F-BD84-6AD1C4E7975E

Q34092334-0B9F1A49-1EE6-46CF-991C-AE33811348CD

Q34092334-22B0C2C8-DB28-4223-A18B-1CCD9C037BD7

Q34092334-24767C33-1EF1-4E18-8656-690D982219A4

Q34092334-26969446-E0D1-4405-9BED-1CDB42FDBF4F

Q34092334-2F544795-EBDC-4B04-9BC6-49C4B324F891

Q34092334-33D9D866-8B5B-49DC-886F-000726F83E96

Q34092334-39CF7C78-5585-463B-9A1A-9C9EDE6EF4A9

Q34092334-40498814-95A4-423C-B166-B1849CA6881A

Q34092334-43053BC5-8685-4CF5-A4D3-11BE7CBD86CC

P304

Q34092334-5942987F-2DE8-4F02-8FDB-4C6B33E05A57

P31

Q34092334-C40A1BD3-CBF0-4517-AFAE-421022BBFEC4

P356

Q34092334-8451CBB5-9662-489C-BE97-C837F2ED8955

P407

Q34092334-D599CE02-2661-4477-BE7B-B5ED5F3A183D

P433

Q34092334-31777063-E3EF-418E-81CC-5FD21203D84A

P478

Q34092334-D5454CA0-0BBA-43E2-87F9-7574E94E8A1B

P50

Q34092334-104C2E23-E179-4CAA-95D0-3333A16AF760

Q34092334-23408205-3868-4671-87F1-00BDE490E31E

Q34092334-311DDDD2-86D3-490C-813D-8010EBBC56E2

Q34092334-66E6D5E8-4189-4FF5-BFC2-EE78A97DDF38

Q34092334-9CB774D6-2148-4E97-B5AD-D062460F4DE2

Q34092334-CEA91413-427E-467E-9866-AACDAD091D3A

Q34092334-F41E463E-1594-4AD1-8651-316B61153528

Q34092334-F8995C75-5314-45A9-9E3F-32801D07D462

Q34092334-F89E680C-16FE-4268-9DA2-717061F2327D

P577

Q34092334-698C014B-525A-409E-BCE0-26D48004992C

P5875

Q34092334-5AA397D9-ED4B-41D1-A249-BEACB5E3AD6B

P698

Q34092334-6FDBF88E-C832-4A95-A7D2-0E2D2F943660

P932

Q34092334-C7263585-2301-4E3D-B2D1-CD28EB18EC01

P356

GUTJNL-2013-306202

P1433

P1476

Targeting mTOR dependency in pancreatic cancer

@en

P2093

Agata Mrowinska

http://www.w3.org/2001/XMLSchema#string

Amy Y M Au

http://www.w3.org/2001/XMLSchema#string

Australian Pancreatic Cancer Genome Initiative (APGI)

http://www.w3.org/2001/XMLSchema#string

C Ross Carter

http://www.w3.org/2001/XMLSchema#string

Christopher J Scarlett

http://www.w3.org/2001/XMLSchema#string

Colin J McKay

http://www.w3.org/2001/XMLSchema#string

Douglas C Morran

http://www.w3.org/2001/XMLSchema#string

Gabriela Kalna

http://www.w3.org/2001/XMLSchema#string

Gerry Gillen

http://www.w3.org/2001/XMLSchema#string

Malgorzata Z Pajak

http://www.w3.org/2001/XMLSchema#string

P2860

Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes

Distant metastasis occurs late during the genetic evolution of pancreatic cancer

First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors.

Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes

Rapamycin blocks the phosphorylation of 4E-BP1 and inhibits cap-dependent initiation of translation

Quantitative phosphoproteomics reveal mTORC1 activates de novo pyrimidine synthesis

Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

P304

1481-1489

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/GUTJNL-2013-306202

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

63

http://www.w3.org/2001/XMLSchema#string

P50

Jennifer P. Morton

Sean M. Grimmond

P577

2014-04-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

261519575

http://www.w3.org/2001/XMLSchema#string

P698

24717934

http://www.w3.org/2001/XMLSchema#string

P932

4145424

http://www.w3.org/2001/XMLSchema#string